Navigation Links
ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
Date:6/23/2008

ADDISON, Texas, June 23 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) announced today that Ronald A. Ahrens has been appointed to serve on the Company's Board of Directors.

Mr. Ahrens has been an advisor to Merck & Company, Inc. since 1995, when he retired as President of Merck Consumer Healthcare Group Worldwide. He had previously served as Executive Vice President of Merck Consumer Healthcare Group International. From 1985 to 1990 Mr. Ahrens was Consumer Group President, North America of Bristol-Myers Squibb and previously was President of Bristol Myers Products Division. Prior to 1985, he held senior management and sales and marketing positions with Richardson Vicks, Bristol-Myers Squibb and Procter and Gamble.

"I am extremely impressed with ULURU's range of innovative products and look forward to providing insight and guidance as they commercialize their numerous product opportunities. The company is now at a point where I believe my experience can assist the company to enhance share holder value," said Mr. Ahrens.

Commenting on the appointment, Kerry P. Gray, President and Chief Executive Officer of ULURU, stated, "We are excited to have Ron join our Board, as he has vast experience successfully commercializing numerous products, and has been involved with a wound care company. His extensive industry experience and contacts will be extremely helpful as we commercialize products both internally and with strategic partners."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com'/>"/>

SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
9. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
10. ULURU Inc. Reports First Quarter 2008 Financial Results
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)..., Dec. 2 To support medication-sa...um (UHC) and Safecor Health, LLC, announced today ...ment for bar-coded pharmaceutical repackaging serv..., , "UHC is very pleased with the addition ...f agreements and is excited to embark on a partner...
(Date:12/2/2008)...Prevention, Shedding, or Sharing Costs as Key , ...-- A New Center for State and Local Government Exc...etiree health care plans and their need to contain...rican States examines how state administrators pe...its to central human resources (HR) goals; how the...
(Date:12/2/2008)...o 70 Cities and Regions by 2010 , , PRINCET... first investment of a new $44 million initiative,...rded grants of up to $400,000 to nine communities ...s for its most ambitious effort yet to reverse the...ids, Healthy Communities will support local actio...
(Date:12/2/2008)... aprotinin, a drug commonly used to control blood ...ared with lysine analogues, according to a study ...e published in the January 20th issue of CMAJ . ... panel will meet to decide on aprotinin use. The s...ting. , The study, a systematic review of 49 ra...
Breaking Medicine News(10 mins):Health News:UHC and Safecor Health Announce Multi-Year Agreement for Repackaging Bar-Coded Medications 2Health News:States View Limits on Retiree Health Benefits 2Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 2Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 3Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 4
...o scientists Vivian Cheung and Warren Ewens from t...isorders that are recessively inherited. Gene exp...ould differ significantly and this new diagnostic ...echnology to identify differences in genome-wide e...
...ing cattle with many growth hormones that are extr... among EU nations that import beef, necessitating ...expert and a pharmaceutical chemist, John Verrall ...ts of consuming beef from cattle that have been in...
...ers, a woman who lost her husband to AIDS and is n...in her Bihar home. Premila Devi, 40, from Tilaei ...ing into a well Saturday, just a few months after ...d of AIDS. "She was upset by the way her family m...
... babies’ to be overweight, which is thought to be ...’ diet during pregnancy. A study that analyzed nea... UK, the Scottish babies’ weight scored the highes...tuation can be remedied if pregnant women were mad...
Other Medicine News:Health News:New Diagnostic Tool Uncovered Gene Expression Patterns in Recessive Genetic Disorders 2
(Date:12/1/2008)...NB-0040 at Children,s Hospital, Health Sciences Ce...wswire/ -- Enobia Pharma, an emerging Canadian bio...ics for serious bone disorders, today announced th...m for hypophosphatasia was dosed. Enobia is invest...0040 for the treatment of this rare and often crip...
(Date:12/1/2008)...-FirstCall/ -- Following a,Request for Proposal i...sed,third generation smallpox vaccine, Public Wo...the Canadian Department of National Defence, has a...very of IMVAMUNE(R). , The Canadian authori...ntry,s bio-preparedness programme. , The co...
(Date:11/30/2008)...wire/ -- Older adults who exercise regularly show ... of small blood vessels in the brain, according to... the Radiological Society of North America (RSNA)....ty of North Carolina ( UNC) - Chapel Hill , is th... exercise to brain scans of those who do not. , ...
(Date:11/27/2008)...astic leukemia relapse cases arise from a cell alr...EMPHIS, Tenn., Nov. 27 ...l have identified distinctive genetic changes in t...ic leukemia (ALL) that cause relapse. The finding ...elapse in children and, ultimately, in adults. , ...
Breaking Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 29545 1Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 29545 2Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 29545 3Drug Resistant TB Declines in United States 29543 1Drug Resistant TB Declines in United States 29543 2Study 3A Smoking Ban Would Help Reduce Heart Attack Admissions 29538 1Study 3A Smoking Ban Would Help Reduce Heart Attack Admissions 29538 2Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 29534 1Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 29534 2Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 29534 3Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 29534 4Independence Blue Cross Celebrates 70 Years Of Service In Southeastern Pennsylvania 29534 5
... WIRE)--Jul 11, 2007 - The Journal of the,American...rly,results of a clinical study conducted by Dr. S...hat the topical gel, Regenecare(R),caused a stati...hing of a rash that results from the use of anti-c... supportive care trial is,listed on the National C...
...tributing Editor , ,Celiac disease (CD) is an...stine that is triggered in genetically susceptible... grains wheat, rye, barley, and possibly oats. The...n of both a T-cell and B-cell immune response, lea... crypt hyperplasia, and is self-perpetuating with ...
Other Medicine Technology:Clinical Study Shows Regenecare Relieves Pain and Itching of Skin,Rashes Caused by Widely Used Cancer Drugs 2Non-Invasive Diagnostic Tests for Celiac Disease 2Non-Invasive Diagnostic Tests for Celiac Disease 3
For determination of HDL-cholesterol in serum and plasma. For Hitachi 717. Specific immunochemical inhibition of non-HDL-lipoproteins. Excellent correlation with established reference methods. Endpoi
Cholesterol/HDL Standard 50 mg/dl.
Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included.
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L
Medicine Products: